NASDAQ: ONTX was devalued by Zacks Research from a “get” rating to a “hold” ranking in a research note released to capitalists on Thursday, Zacks.com records.
According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on discovering as well as developing little molecule medicine candidates to treat cancer cells. The Firm‘s items under different stages of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
A number of various other equities research experts also lately talked about the firm. Noble Financial reissued a “buy” ranking as well as provided a $11.00 rate goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and set a “purchase” rating on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day relocating average cost of $2.90 as well as a two-hundred day relocating typical cost of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, covering analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and an adverse net margin of 8,294.27%. The company had profits of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. During the exact same quarter in the prior year, the company posted ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will upload -1.18 EPS for the existing year.
A number of hedge funds have lately bought and sold shares of ONTX. GSA Funding Partners LLP purchased a brand-new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Management LP got a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional financiers possess 13.36% of the business’s stock.
Regarding Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the identification and growth of oncology therapeutics. It focuses on discovering and also establishing small molecule medication prospects to deal with cancer. The business was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA
. Get a cost-free copy of the Zacks research report on Onconova Therapeutics (ONTX).
For additional information about research offerings from Zacks Investment Research, go to Zacks.com.
This instantaneous news alert was produced by narrative science innovation as well as financial information from Market in order to give readers with the fastest as well as most accurate reporting. This tale was reviewed by Market’s editorial group before magazine.
SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?
Before you think about Onconova Therapeutics, you’ll wish to hear this.
Market tracks Wall Street’s top-rated and best executing research experts as well as the stocks they recommend to their customers each day. Market has actually identified the five stocks that top analysts are silently murmuring to their customers to acquire currently before the wider market catches on … and Onconova Therapeutics wasn’t on the checklist.
While Onconova Therapeutics currently has a “Buy” score among experts, premier analysts believe these 5 stocks are much better acquires.